Alcidion Group reports $51.6M FY26 revenue
- Alcidion Group reported full-year FY26 revenue of $51.6 million, marking a 27% increase compared to the previous year.
- The company recorded underlying EBITDA of $6.8 million.
- Management expects the recent acquisition of Kyra Flow products to expand its customer base and deepen its presence in the patient flow market.
Alcidion Group (ASX:ALC) reported a 27% increase in FY26 revenue to $51.6 million alongside record profitability metrics.
The result reflects a 34% increase in underlying EBITDA to $6.8 million compared to the previous year. Net profit after tax grew 38% to $2.3 million.
"Throughout the year we continued to build and expand relationships with our enterprise customers, validated by over $150M of new and renewal contract value being won over the past 2 years, generally on multi-year contract terms," said Alcidion Group CEO and Managing Director Kate Quirke.
The company ended the period with a $20.6 million cash balance, zero debt and $44.9 million in contracted FY27 revenue.
The company’s acquisition of KyraFlow products expands Alcidion’s customer base in Australia.
Alcidion expects FY27 revenue and underlying EBITDA to outperform FY26.
Following the announcement, the Alcidion Group share price was unchanged at $0.094.
The firm develops clinical decision support systems and electronic patient records for healthcare providers across core international markets.
Management stated that the global patient flow market is forecast to grow at an 18% compound rate through 2034.
